Samsung Bioepis launches Lucentis biosimilar in Canada, Germany
IndustryMar 5, 2023
South Korean biotech firm Samsung Bioepis is expanding into the global market with SB11, a biosimilar drug used to treat ophthalmologic diseases such as macular degeneration. According to industry sources on Sunday, SB11 was introduced to the Canadian market last Wednesday through its partner company Biogen, following an earlier launch in Germany on Feb. 23. SB11 references Lucentis, a drug developed by global pharmaceutical company Genentech. It received sales approval in Europe and the US unde